SomnoMedASX:SOM +0.94%50 FCF Yield % is 1.60 as of Jun. 28, 2026. GuruFocus rates ASX:SOM with a GF Score™ of 50/100 and a GF Value™ of A$0.45 (Modestly Overvalued). The stock has 3 warning signs investors should review. Among 855 Medical Devices & Instruments companies, SomnoMed ranks better than 61.99% on this metric.
FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
The historical rank and industry rank for SomnoMed's FCF Yield % or its related term are showing as below:
ASX:SOM'
s FCF Yield % Range Over the Past 10 Years
Min: -48.49 Med: -4.36 Max: 3.84
Current: 1.6
During the past 13 years, the highest FCF Yield % of SomnoMed was 3.84%. The lowest was -48.49%. And the median was -4.36%.
ASX:SOM's FCF Yield % is ranked better than 61.99% of 855
companies
in the Medical Devices & Instruments industry
Industry Median: -0.38
vs ASX:SOM: 1.60
Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
SomnoMed FCF Yield % Related Terms
SomnoMed FCF Yield % Historical Data
* Premium members only.
The historical data trend for SomnoMed's FCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, SomnoMed's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
SomnoMed FCF Yield % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, SomnoMed's FCF Yield % distribution charts can be found below:
* The bar in red indicates where SomnoMed's FCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SomnoMed (ASX:SOM) has a FCF Yield % of 1.60 as of Jun. 28, 2026. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on SomnoMed and its competitors. According to the industry distribution chart, SomnoMed ranks #325 out of 855 companies in the Medical Devices & Instruments industry, placing it in the top 38%.
Is SomnoMed's FCF Yield % too high?
SomnoMed's current FCF Yield % is 1.60. Based on the distribution chart, SomnoMed ranks #325 out of 855 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, SomnoMed has a GF Score™ of 50/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does SomnoMed's FCF Yield % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, SomnoMed ranks #325 out of 855 companies for FCF Yield %. This puts SomnoMed in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Yield % for a Medical Devices & Instruments company?
A good FCF Yield % depends on the Medical Devices & Instruments industry context. However, FCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Yield % mean?
A high FCF Yield % can signal that a stock is expensive relative to its fundamentals. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on SomnoMed and its competitors. SomnoMed's current FCF Yield % is 1.60. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SomnoMed stock overvalued right now?
Based on GuruFocus' analysis, SomnoMed (ASX:SOM) is currently considered Modestly Overvalued. The stock's GF Value™ is A$0.45, compared to a current price of A$0.54 — trading 18.9% above its estimated fair value. The current FCF Yield % is 1.60. SomnoMed's overall GF Score™ is 50/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Yield % calculated?
FCF Yield % is calculated from a company's financial statements. For SomnoMed (ASX:SOM), the current FCF Yield % is 1.60 as of Jun. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is SomnoMed (ASX:SOM) Overvalued in 2026?
Based on GuruFocus' analysis, SomnoMed stock appears to be overvalued.
The current stock price of A$0.54 is trading 18.9% above its estimated GF Value™ of A$0.45.
GuruFocus considers SomnoMed to be Modestly Overvalued.
Key valuation signals for ASX:SOM:
FCF Yield %: 1.60
GF Value™: A$0.45 vs. price of A$0.54 (18.9% above fair value)
No single metric tells the full story. See the ASX:SOM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
SomnoMed Ltd provides treatment solutions for sleep-related breathing disorders, including obstructive sleep apnea, snoring, and bruxism. It is engaged in commercializing SomnoDent Mandibular Advancement Splint (MAS) and other oral devices for sleep-related disorders in Australia and overseas. The other products in the company's portfolio include SomMorning Repositioner; SomnoBrux splint, a custom-fit, acrylic splint (dental guard) for upper teeth designed to protect teeth from grinding and scraping during Bruxism; and SomTabs cleaning tablets that have been developed to clean oral appliances. Geographically, the company generates maximum revenue from Europe, followed by North America and the Asia Pacific region.
50GF Score
Get the complete analysis for ASX:SOM
FCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:SOM has been successfully added to your 
